Chemoimmunotherapy before surgery for limited spread esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a treatment plan that combines chemotherapy with immunotherapy, followed by surgery, for people whose esophageal or stomach cancer has spread to a few areas (oligometastatic). The goal is to see if this approach can shrink the cancer and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a type of esophageal or stomach cancer that has spread to up to 5 spots in no more than 2 organs (like liver, lung, or adrenal gland).
- You are between 18 and 80 years old.
- You are in good enough health to undergo surgery and the planned treatments, with a performance status of 0 or 1 (able to carry out daily activities).
- Your heart, lungs, and blood work (like kidney and liver function) are adequate for systemic therapy.
- You do not have widespread cancer in the lining of your abdomen or chest, or multiple brain or bone metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests whether adding immunotherapy to chemotherapy before surgery works better than chemotherapy alone for resectable esophageal cancer. The goal is to improve outcomes after tumor shrinkage before the operation.
This trial tests combining chemotherapy, immunotherapy, and radiation before surgery for stomach or gastroesophageal junction cancer that has spread to a limited number of sites. The goal is to see if this approach can improve outcomes by shrinking tumors before they are removed.
This trial tests whether giving chemotherapy and immunotherapy before surgery is safe and effective for older adults (70+) with a certain type of esophageal cancer. It aims to find a treatment approach that works well for patients who haven't had cancer treatment before.
This trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (given before surgery) can help shrink stage II/III esophageal cancer. The goal is to make surgery more likely to remove all cancer and improve outcomes.
This trial tests whether giving chemotherapy combined with immunotherapy before surgery works better than the standard chemoradiation for esophageal cancer that can be removed. It may help reduce tumor size and improve outcomes.
This trial tests a treatment plan that combines chemotherapy and immunotherapy before surgery, followed by radiation and immunotherapy after surgery for people with esophageal squamous cell cancer. It aims to see if this approach helps prevent the cancer from coming back.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.